Results 141 to 150 of about 6,339,362 (215)
Electrophysiology’s Identity Crisis: What our Clinical Trials Do and Do Not Say About Us
Arrhythmia & Electrophysiology Review, 2020 David J Callans +2 more
doaj +1 more source
Leucine‐rich glioma inactivated 1 (LGI1) is a ganglioside‐binding protein
FEBS Letters, EarlyView.Neuronal hyperexcitability associated with a decrease/absence of the extracellular protein LGI1 has been suggested to be primarily due to the downregulation of Kv1 channel expression. The molecular mechanisms underlying this decrease have not yet been elucidated.
Kévin Debreux +7 more
wiley +1 more source
A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma
FEBS Letters, EarlyView.Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos +9 more
wiley +1 more source
HIV/AIDS: Research and Palliative CareJustina J Maganga,1,2 Andrew Katende,1,3 Ezekiel Luoga,3 Nancy Nshatsi,2,4 Jamal Siru,1,3 George Sigalla,1,3 Clara Mollay,2 Maja Weisser,1,3,5,6 Sally Mtenga7 1Interventions and Clinical Trials, Ifakara Health Institute, Morogoro, Tanzania; 2The Nelson ...
Maganga JJ +8 more
doaj
Metastatic niche shaped by host factors influences disseminated cancer cell fate
FEBS Letters, EarlyView.Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward +2 more
wiley +1 more source
Dose selection in seamless phase II/III clinical trials based on efficacy and toxicity [PDF]
Seamless phase II/III clinical trials are attractive in development of new drugs because they accelerate the drug development process. Seamless phase II/III trials are carried out in two stages.
Kimani, Peter K.
core
Smaller is better: nanobodies meet NMR
FEBS Letters, EarlyView.Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley +1 more source
Neutralization of the PTX3/CD44 axis suppresses TGF‐β1 signaling in kidney fibrosis
FEBS Letters, EarlyView.This study investigates how the PTX3/CD44 axis promotes kidney fibrosis by activating TGF‐β1 signaling. We demonstrate that the neutralizing antibody WHC‐001 effectively inhibits this pathway, suppressing myofibroblast activation and partial epithelial–mesenchymal transition (EMT).
Chao‐Chun Cheng +8 more
wiley +1 more source
Inhibition of dipeptidyl peptidase 7 impairs lysophagy in LLOMe‐treated HepG2 cells
FEBS Letters, EarlyView.DPP7 inhibition delays ubiquitin‐dependent lysophagy by attenuating ubiquitin accumulation and the recruitment of SQSTM1 and LC3 to damaged lysosomes, resulting in delayed clearance of damaged lysosomes and impaired restoration of lysosomal homeostasis. Created using FigureLabs (Certificate ID: FL‐PUB‐20260922‐Z99XNX).
Na Yeon Park +8 more
wiley +1 more source
Collective Equipoise, Disappointment and the Therapeutic Misconception: On the Consequences of Selection for Clinical Research [PDF]
Private information induces individuals to self-select as subjects into clinical research trials, and it induces researchers to select which trials they conduct.
Margaret M. Byrne, Peter Thompson
core